• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Publisher version
    View Source
    Access full-text PDFOpen Access
    View Source
    Check access options
    Check access options
    Author
    McCoach, Caroline E
    Rolfo, Christian
    Drilon, Alexander
    Lacouture, Mario
    Besse, Benjamin
    Goto, Koichi
    Zhu, Viola W
    Tan, Daniel Sw
    Farajian, Stephanie
    Potter, Laura A
    Kherani, Jennifer F
    Soldatenkova, Victoria
    Olek, Elizabeth A
    Muehlenbein, Catherine E
    Park, Keunchil
    Show allShow less

    Date
    2022-02-17
    Journal
    Journal of Thoracic Oncology
    Publisher
    Elsevier
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1016/j.jtho.2022.02.004
    Abstract
    Introduction: Immune checkpoint inhibitor (ICI) therapy has been shown to increase the risk/severity of immune-mediated adverse events with subsequent kinase inhibitor treatment in oncogenically-driven cancers. We explored the risk for hypersensitivity with selpercatinib, a first-in-class highly selective and potent, CNS-active RET inhibitor, in prior ICI-treated patients with RET fusion-positive non-small-cell lung cancer (NSCLC) compared with their ICI-naïve counterparts. Methods: Data from patients enrolled by 16-December-2019 in the ongoing phase 1/2 LIBRETTO-001 (NCT03157128) trial were analyzed for hypersensitivity reactions reported using preferred terms hypersensitivity/drug hypersensitivity and defined as a constellation of symptoms/findings characterized by maculopapular rash, often preceded by fever with arthralgias/myalgias, followed by ≥1 of the following signs/symptoms: thrombocytopenia, increased AST/ALT, hypotension, tachycardia, and/or increased creatinine. Results: Twenty-two of 329 (7%) patients experienced a grade 1-3 hypersensitivity reaction that met the defined constellation of events were attributed to selpercatinib by investigators, and more often in prior ICI-treated (n=17, 77%) than ICI-naïve (n=5, 23%) patients. Nineteen patients with selpercatinib-related hypersensitivity resumed selpercatinib post-hypersensitivity with dose modification/supportive care. Seventeen patients, of whom 14 received prior ICI therapy, were still on treatment at twice-daily doses of 40 mg (n=5), 80 mg (n=4), 120 mg (n=4), and 160 mg (n=4). Conclusions: Rates of selpercatinib-related hypersensitivity were low overall and as with other kinase inhibitors, occurred predominantly in prior ICI-treated patients. Hypersensitivity to selpercatinib can be managed with supportive care measures regardless of prior ICI status and are reversible.
    Rights/Terms
    Copyright © 2022. Published by Elsevier Inc.
    Keyword
    Hypersensitivity
    immune checkpoint inhibitor
    non-small-cell lung cancer
    selpercatinib
    supportive care
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/18105
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.jtho.2022.02.004
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Efficacy of immune checkpoint inhibitor therapy in patients with <i>RET</i> fusion-positive non-small-cell lung cancer.
    • Authors: Bhandari NR, Hess LM, Han Y, Zhu YE, Sireci AN
    • Issue date: 2021 Aug
    • Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
    • Authors: Minchom A, Tan AC, Massarelli E, Subbiah V, Boni V, Robinson B, Wirth LJ, Hess LM, Jen MH, Kherani J, Olek E, McCoach CE
    • Issue date: 2022 Feb 3
    • Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    • Authors: Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC, Olek EA, Scanlon JE, Vojnic M, Ebata K, Hechtman JF, Li BT, Sholl LM, Taylor BS, Ladanyi M, Jänne PA, Rothenberg SM, Drilon A, Oxnard GR
    • Issue date: 2021 Jan 1
    • Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.
    • Authors: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V
    • Issue date: 2020 Aug 27
    • Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    • Authors: Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, Lamberg K, Hashemi SMS, Huemer F, Vikström A, Wermke M, Absenger G, Addeo A, Banerji S, Calles A, Clarke S, Di Maio M, Durand A, Duruisseaux M, Itchins M, Kääränien OS, Krenn F, Laack E, de Langen AJ, Mohorcic K, Pall G, Passaro A, Prager G, Rittmeyer A, Rothenstein J, Schumacher M, Wöll E, Valipour A
    • Issue date: 2021
    DSpace software (copyright © 2002 - 2022)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.